Avita Medical Ltd. (AVMXY: OTCQX International) | ReCell(R)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Avita Medical Ltd. (AVMXY: OTCQX International) | ReCell(R) Spray-on Skin(R) Demonstrates Superior Results Treating Hypopigmentation in Aesthetic Plastic Surgery Trial ReCell(R) Spray-on Skin(R) Demonstrates Superior Results Treating Hypopigmentation in Aesthetic Plastic Surgery Trial

ReCell(R) Spray-on Skin(R) Demonstrates Superior Results Treating Hypopigmentation in Aesthetic Plastic Surgery Trial

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - May 15, 2014) - Avita Medical Limited ( ASX : AVH ) ( OTCQX : AVMXY )

Highlights

  • Clinical study interim results demonstrate ReCell® superiority as treatment for hypopigmentation.
  • Statistically significant pigment restored in patients' hypopigmented scars treated with ReCell.
  • Results support the Company's commercial strategy for use of ReCell in aesthetic plastic surgery.
  • Study results delivered at key European conferences, enhancing ReCell industry profile.

Regenerative medicine company Avita Medical Limited "Avita Medical" ( ASX : AVH ) ( OTCQX : AVMXY ) is pleased to announce that its product, ReCell, has been proven in a clinical study in Germany to provide clinically superior results for the treatment of hypopigmented scars.

The ongoing study by German-based Associate Professor Dr Matthias Aust, found that areas treated with ReCell combined with a scar treatment technique called medical needling showed statistically significant repigmentation, while the areas treated with medical needling alone and not treated with ReCell, did not.

The results of the study were presented by Mr Richard Bender, a student of Dr Aust, in a presentation entitled "Combination of Medical Needling and ReCell -- a promising method?" at the VDAEPC (Association of German Aesthetic Plastic Surgeons). The presentation was awarded the conference's "Best of Europe" prize and as a result has been selected to be delivered as a German keynote lecture at the European Association of Societies of Aesthetic Plastic Surgery (EASAPS) in November 2014.

Avita Medical VP Research & Technology Mr Andrew Quick said that the results of the clinical study provide further demonstration of the benefits of using ReCell to treat hypopigmented scars and that the aesthetic plastic surgery conferences are an excellent platform to share the beneficial outcomes with medical professionals.

"This is a particularly important study for ReCell as it is a randomised controlled design with an objective measure showing statistically significant repigmentation outcomes," Mr Quick said.

In the study, each of the 18 participants had some hypopigmented scar area treated with needling, and other hypopigmented scar area treated with a combination of needling and ReCell. In the 12 months following the ReCell treatment, the participants were monitored using a medical device that detects levels of melanin in the skin.

Medical needling, or percutaneous collagen induction, is a scar treatment approach that improves many properties of scar tissue, but often does not restore pigment, particularly for large scar areas. Dr Aust hypothesized that adding ReCell to the scar treatment would result in greater repigmentation than can be achieved with the needling alone, and the results have shown that he was correct.

Associate Professor Dr Matthias Aust said: "The clinical study carried out by my research group found that the combination of the two procedures, needling and ReCell, shows positive results.

"We believe that we have found a method for preparation of the treatment site without removing any skin tissue, and that with both needling and ReCell, we can reliably achieve improvement in repigmentation."

Avita Medical Interim Chief Executive Officer Mr Tim Rooney said that the clinical study results were important in providing definitive evidence to clinicians that ReCell is an effective treatment for hypopigmentation.

"Dr Aust's results clearly show that ReCell is an effective method for repigmentation and we're proud that the presentation has been selected to be delivered later this year at the EASAPS."

ABOUT AVITA MEDICAL LIMITED

Avita Medical ( http://www.avitamedical.com ) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue‐culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell® Spray‐On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE‐marked for Europe, TGA‐registered in Australia, and SFDA‐cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

FOR FURTHER INFORMATION:

Avita Medical Ltd.
Ian Macpherson
Chairman
Phone: +61 (0) 8 9474 7738
Email: imacpherson@avitamedical.com

Avita Medical Ltd.
Tim Rooney
Acting Chief Executive Officer/Chief Financial Officer
Phone: + 1 (818) 827-1695
Email: trooney@avitamedical.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 143

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 0

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 73

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Lennar Lawsuit Puts Land-Light Claims Under a Microscope

Updated Category News Views 65

Three ugly selloffs, a murky land-bank story, and a fresh securities complaint have turned Lennar into the sort of holding that makes shareholders reread every footnote. The lawsuit is not a verdict, and the allegations remain unproven, but the timeline is nasty enough that investors in NYSE:LEN should not shrug it off as ordinary housing-cycle turbulence. The Dates...

Continue Reading
Allstate's October Cat Loss Lands at $232 Million Net

Updated Category News Views 40

October’s weather bill arrived without much poetry: $232 million in estimated catastrophe losses at Allstate. Reported on November 19, that figure falls to $184 million after tax, and it deserves a clear-eyed read rather than the usual insurance-stock theatrics. A single monthly catastrophe tally is not a verdict on the company, but it is absolutely part of the...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 41

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 65

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Cooperate Marketing Lands 318th on Deloitte Fast 500

Updated Category News Views 49

A 199% revenue jump over three years will get my attention before any shiny award logo does. Cooperate Marketing says it grew that much from 2022 through 2025, enough to place No. 318 on Deloitte's 2026 Technology Fast 500 list. For a privately held Chicago marketing-technology outfit, that is a legitimate operating milestone, not just another ribbon to pin on the company...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 159

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 130

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Puede Unirse a la Demanda Colectiva sobre RxSight, Inc.

Updated Category News Views 234

Oportunidad para Inversionistas de RxSight, Inc. Inversionistas en RxSight, Inc. (NASDAQ: RXST) están ante una oportunidad única de unirse a una demanda colectiva en defensa de sus derechos. Recientemente, se ha producido un aumento en las preocupaciones relacionadas con las declaraciones realizadas por la compañía, que parecen haber conducido a pérdidas...

Continue Reading
Enprotech's New Field Service Office: Enhancing Equipment Support

Updated Category News Views 199

Enprotech Expands Operations with New Field Service Office Enprotech, a leading North American provider of heavy equipment repair and modernization services, is thrilled to announce the grand opening of its new Field Service Office. This new facility highlights Enprotech's commitment to operational excellence and aims to enhance customer support across various...

Continue Reading
Standard Lithium's Bold Steps Towards Sustainable Lithium Production

Updated Category News Views 183

Standard Lithium's Progress and Strategic Developments VANCOUVER, British Columbia — Standard Lithium Ltd. (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leader in lithium development, recently shared their financial and operational updates as they wrapped up the fiscal year. With a bold vision, Standard Lithium has made impressive advancements in strengthening its...

Continue Reading
Allegations of Price-Fixing Impacting Private College Costs

Updated Category News Views 96

Allegations of Price-Fixing Impacting Private College Costs Recently, a major class-action lawsuit has come to light against 40 prestigious private colleges and universities, including renowned institutions like MIT, NYU, and Brown. This legal action contends that these schools have engaged in a conspiracy through the College Board to inflate tuition costs, potentially...

Continue Reading
Seaboard Corp Stock Plummets Amidst Market Challenges

Updated Category News Views 84

Seaboard Corporation Faces Significant Stock Decline Seaboard Corporation (SEB) has recently hit a notable milestone in its stock performance, reaching a 52-week low price of $2409.58. This dip in the stock price comes amidst a turbulent market environment, reflecting broader trends affecting the company and its operational sectors. Despite the current market challenges,...

Continue Reading